Citations 2
A randomized phase II trial of the MET inhibitor tivantinib + cetuximab versus cetuximab alone in patients with recurrent/metastatic head and neck cancer.
Bauman, Julie E. , Lim, Dean, Sukari, Ammar , Wagner, Stephanie A., Curtis, Kelly K., Gitlitz, Barbara J. , Price, Katharine A. , Wade, James L. , Villaflor, Victoria , Souza, Jonas A. de, Karrison, Theodore , Vokes, Everett E. , Worden, Francis P. , Adkins, Douglas R. , Rao, Krishna A , Stadler, Walter M. , Seiwert, Tanguy Y.
Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 6060-6060
Effect of the addition of temsirolimus to cetuximab in cetuximab-resistant head and neck cancers: Results of the randomized PII MAESTRO study.
Chawla, Apoorva, Hu, H. Shawn, Price, Katharine A. , Zavala, Jose D, Karrison, Theodore , Villaflor, Victoria , Adkins, Douglas R. , Worden, Francis P. , Rao, Krishna A , Zavala, Jose D, Stadler, Walter M. , Lussier, Yves A. , Vokes, Everett E. , Cohen, Ezra E.W. , Seiwert, Tanguy Y.
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 6089-6089